The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 338:1741-1751 June 11, 1998 Number 24
NextNext

Infection in Organ-Transplant Recipients
Jay A. Fishman, M.D., and Robert H. Rubin, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
A primary goal in organ transplantation is the prevention or effective treatment of infection, the most common life-threatening complication of long-term immunosuppressive therapy. The challenges involved in achieving this goal are several: a broad range of potential sources of infection ranging from latent viruses to pathogens of both community and hospital origin; immunosuppression-induced impairment of the inflammatory response, which attenuates the signs and symptoms of invasive infection; and the adverse effects of the antimicrobial drugs used for prophylaxis and therapy, which result both from the duration of therapy required and from interactions with the immunosuppressive drugs cyclosporine and tacrolimus. Our . . . [Full Text of this Article]

Risk of Infection in Transplant Recipients

Epidemiologic Exposure

The Net State of Immunosuppression

Timetable for Infection after Transplantation

Infection in the First Month after Transplantation

Infection One to Six Months after Transplantation

Infection More Than Six Months after Transplantation

Evaluation of the Donor and Recipient before Transplantation

Principles of Antimicrobial Therapy in Transplant Recipients

Strategies for Antimicrobial Therapy

            Prophylaxis

            Preemptive Therapy

Drug Toxicity in Transplant Recipients

Infections of Particular Importance in Transplant Recipients

CMV

EBV and Post-Transplantation Lymphoproliferative Disease

Fever and Pneumonitis

Central Nervous System Infection

Conclusions and Future Directions


Source Information

From the Program in Transplantation Infectious Disease, Massachusetts General Hospital, Boston (J.A.F., R.H.R.); Harvard Medical School, Boston (J.A.F.); and the Center for Experimental Pharmacology and Therapeutics, Division of Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of Technology, Cambridge, Mass. (R.H.R.).

Address reprint requests to Dr. Rubin at the Program in Transplantation Infectious Disease, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114.

References


Related Letters:

Infection in Organ-Transplant Recipients
Gómez-Moreno J., Cuervas-Mons V., Ridzon R., Onorato I. M., Palmer S. M., Tapson V. F., Stamm A. M., Fishman J. A., Rubin R. H.
Extract | Full Text  
N Engl J Med 1998; 339:1244-1246, Oct 22, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.